ANKRD16: A Drug Target / Disease Biomarker (G54522)

Target Name: ANKRD16

NCBI ID: G54522

ANKRD16

ANKRD16: A Drug Target / Disease Biomarker

ANKRD16.0 is a drug target and a potential biomarker for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It is a transmembrane protein that is expressed in various tissues and cells in the body. ANKRD16.0 plays a crucial role in cell signaling, specifically in the regulation of cell adhesion, migration, and survival.

The ANKRD16.0 gene was first identified in 2003 by researchers at the University of California, San Diego (UCSD) as a potential drug target for neurodegenerative diseases. The gene is located on the X chromosome and has been shown to be involved in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time.

Since its identification, numerous studies have been conducted to investigate the functions and potential therapeutic applications of ANKRD16.0. These studies have demonstrated that ANKRD16.0 plays a crucial role in the development and progression of various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia.

One of the most significant findings related to ANKRD16.0 is its involvement in the regulation of dopamine signaling. Dopamine is a neurotransmitter that plays a crucial role in mood, motivation, and pleasure, and is often impaired in various psychiatric and neurological disorders. Studies have shown that ANKRD16.0 is involved in the regulation of dopamine signaling in the brain and that it is a potential therapeutic target for the treatment of neurodegenerative disorders.

In addition to its role in dopamine signaling, ANKRD16.0 has also been shown to be involved in the regulation of other signaling pathways that are important for brain development and function. For example, ANKRD16.0 has been shown to be involved in the regulation of cell adhesion, which is the process by which cells stick together to form tissues and organs. This is important for the development and maintenance of tissues and organs, including the brain.

Another potential application of ANKRD16.0 is its role in the regulation of cell survival. Cell death, or apoptosis, is a natural process that is important for the development and maintenance of tissues and organs, including the brain. However, in the case of neurodegenerative disorders, cell death can occur abnormally and contribute to the progression of the disease. Studies have shown that ANKRD16.0 is involved in the regulation of cell survival and that it is a potential therapeutic target for the treatment of neurodegenerative disorders.

In conclusion, ANKRD16.0 is a drug target and potential biomarker for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in cell signaling, particularly in the regulation of dopamine signaling and cell adhesion, makes it an attractive target for therapeutic intervention. Further research is needed to fully understand the therapeutic potential of ANKRD16.0 and to develop safe and effective treatments for the various diseases it is associated with.

Protein Name: Ankyrin Repeat Domain 16

Functions: Required to prevent the misactivation of serine (Ser) with tRNA(Ala) by promoting the hydrolysis of Ser-mischarged tRNA(Ala), thereby playing a role in translational fidelity. Binds directly to the catalytic domain of AARS/AlaRS and captures Ser that is misactivated by AARS/AlaRS, preventing the charging of Ser adenylates to tRNA(Ala) and precluding Ser misincorporation in nascent peptides

The "ANKRD16 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANKRD16 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets